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Time and Circumstances: Cancer 
Cell Metabolism at various Stages 
of Disease Progression
Georg F. Weber*
James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA
Over the past decade, research into the unique ways, in which cancer cells skew their 
metabolism, has had a renaissance—for the repeated time over more than 80 years 
since the discovery of an inherent preference for glycolysis. Importantly, the Warburg 
effect that arises in primary neoplasms is not the sole prominent metabolic phenomenon. 
Once the transformed cells are shed from their initial growth and begin the process of 
metastasis, their energy requirements change and they adapt to the increased demand 
for adenosine triphosphate, which if not satisfied would lead to anoikis. At that stage, 
oxidoreductases and the respiratory chain are activated. Furthermore, the intrinsic met-
abolic characteristics of tumor cells may be influenced by extrinsic factors, comprising 
metabolite secretions from stromal cells or acidification and nutrient deprivation in the 
late-stage hypoxic environment. While there is metabolic adjustment in cancer cells 
throughout the disease history, its phenotypic manifestation changes at various times. 
This stage selectivity has implications for pharmacotherapy ambitions.
Keywords: metabolism, therapeutics, metastasis, hypoxia, glycolysis
A weALTH OF iNFORMATiON
Recent research has rediscovered the metabolic changes that occur in tumor cells during transforma-
tion. Numerous publications have studied the glycolytic preference of cellular energy pathways that 
is prevalent even under normoxic conditions. Yet, this so-called Warburg effect (the observation that 
cancer cells can grow with limited oxygen consumption by engaging glycolysis over mitochondrial 
 respiration—even under conditions of sufficient oxygen supply) is not the only metabolic alteration 
that can arise in cancer cells. While some skewing of the metabolism seems to be inevitable in 
transformation, its presentation changes over the course of the disease. It is important to differentiate 
the various manifestations of cancer-associated metabolic adjustments (1).
The metabolic pathways within tumor cells can be altered endogenously, which is the case in 
the Warburg effect (the cells switch to glycolytic metabolism despite sufficient oxygen supply; if 
the switch occurs in a hypoxic environment, such as in advanced disease, it is not a Warburg effect, 
but an adaptation used by healthy and transformed cells alike). During tumor progression, when 
deadhesion occurs it poses a dramatically increased adenosine triphosphate (ATP) requirement 
that forces the upregulation of energy production. Alternatively, the microenvironment can affect 
the tumor cell metabolism when stromal cells secrete abundant lactate that is then taken up by the 
transformed cells. Obviously, the hypoxic, acidic, low-glucose environment of late-stage cancers 
also has a direct effect on the metabolic processes inside the cancer cells. The connotations of these 
four scenarios (intrinsic, deadherent, stromal-induced, and late-stage) differ among each other in 
underlying mechanisms and resulting phenotypes (Table 1). Consecutively, they require distinct 
TABLe 1 | Stage-dependent alterations in cancer cell metabolism.
Cause effect Potential 
treatment
intrinsic (warburg) P53-deficient tumor cells do not have functional SCO2 or 
TIGAR and display a glycolytic metabolism phenotype
Protect from apoptosis by closing Kv channels and 
preventing the influx of calcium
Dichloroacetate, 
lonidamine
Embryonic M2 isoform of pyruvate kinase shifts cellular 
metabolism to aerobic glycolysis
Satisfaction of anabolic requirements, biosynthetic 
activities by proliferating tumor cells entail the production 
of ribose-5-phosphate for nucleotide biosynthesis, and 
the production of fatty acids for lipid biosynthesis
Deadhesion Deadherent cells suffer deficit in glucose transport, resulting 
in adenosine triphosphate (ATP) deficiency and anoikis
Peroxide signaling, increased mitochondrial activity Anti-oxidants
Serine–glycine–creatine pathway regenerates ATP
Stromal interaction Lactate secretion from mesenchymal cells via the 
transporter MCT4
Tumor cells import this lactate via MCT1 expression, 
converting it to pyruvate and introducing it into the Krebs 
cycle, resulting increased in oxidative phosphorylation and 
ATP production
Hypoxia Hypoxia, low-glucose, lactate Induction of HIF-1, carbonic anhydrase IX Methazolamide
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strategies for ambitions to incorporate metabolic targeting into 
anticancer treatment regimens.
PRiMARY GROwTHS: wARBURG’S 
GLYCOLYSiS
The evolution of respiration has equipped us with a tremendous 
advantage. The oxidative breakdown of glucose, the fuel in bioen-
ergetics, yields 36–38 molecules of ATP per molecule of glucose, 
as opposed to 4–6 molecules of ATP resulting from glycolysis. 
Initially, it seemed paradoxical that tumors, which need more 
chemical energy than healthy cells due to their rapid prolifera-
tion, would preferentially engage the much less efficient glycolytic 
energy production. Two fundamental questions need to be 
addressed to understand this Warburg effect (aerobic glycolysis). 
What causes it and what are its consequences?
Various explanations have been put forward for the molecular 
causes of glycolysis in cancer (2, 3). In healthy cells, P53 sup-
ports ATP generation by stimulating oxidative phosphorylation 
(through the activation of SCO2) and inhibiting glycolysis 
(through the inactivation of PFK-1). P53 directly regulates 
oxidative phosphorylation by stimulating the expression of the 
gene that encodes SCO2, which is essential for the assembly 
of the cytochrome c oxidase complex embedded in the inner 
mitochondrial membrane. The P53-inducible gene TIGAR codes 
for a protein that downregulates the cellular fructose-2,6-bis-
phosphate levels. As fructose-2,6-bisphosphate is an allosteric 
effector of 6-phosphofructose-1-kinase (PFK-1), which promotes 
glycolysis, TIGAR expression attenuates this pathway. Loss of P53 
function is common in human cancers. TP53-deficient tumor 
cells do not have functional SCO2 or TIGAR and display a 
glycolytic metabolism phenotype (4, 5). In addition, functional 
gains may be exerted by TP53 mutations that commonly arise 
in cancer. Mutated P53 stimulates the Warburg effect through 
promoting the translocation of the glucose transporter GLUT1 
to the plasma membrane. This is mediated by activated RHO-A 
and its downstream effector ROCK (6). It is conceivable that the 
abundance of intracellular glucose requires its processing via 
glycolysis rather than via the slower oxidative phosphorylation.
Tumor cells express exclusively the embryonic M2 isoform 
of pyruvate kinase, which is necessary for the shift in cellular 
metabolism to aerobic glycolysis. This switch in a splice variant 
of the glycolytic enzyme allows these cells to proliferate in low 
glucose and limiting oxygen conditions that are common in can-
cer. The division of cells expressing the M1 variant is significantly 
decreased compared to M2 expressing cells in low oxygen (of 
note, this characteristic reflects hypoxia resistance, which is not 
identical to the Warburg effect). Furthermore, pyruvate kinase 
M2 expression provides a selective growth advantage for tumor 
cells in vivo (7).
wARBURG’S eFFeCTS
The reliance by rapidly growing cancer cells on anaerobic 
glycolysis seems counterintuitive. Hence, teleological explana-
tions for why and how the preferred glycolytic metabolism in 
transformation may advance tumor initiation or tumor growth 
have been scant. Two possible justifications associate cancer 
cell glycolysis either with mitochondrial hyperpolarization and 
anti-apoptosis or with the synthesis of essential biomolecules. 
In some cancers, the aerobic glycolysis may support oncogenic 
transcription.
The cell membrane contains a voltage-gated family of potas-
sium channels (Kv), which due to its redox sensitivity can be 
regulated by the mitochondria. As a by-product of respiration, 
the mitochondria produce superoxide, which may be dismutated 
to hydrogen peroxide that activates these channels, thereby regu-
lating the voltage-dependent influx of calcium and the activity 
of caspases. The connection of mitochondria via peroxide to Kv 
channels is involved in oxygen sensing as well as in the promotion 
of apoptosis. Cancer cells would be at risk of cell death if the rapid 
proliferation relied on energy production by the mitochondria, 
thus generating high levels of superoxide and—derived from it—
hydrogen peroxide. However, mitochondrial hyperpolarization 
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occurs in these transformed cells and leads to anti-apoptosis, 
because low hydrogen peroxide and high NFAT suppress the 
plasma membrane potassium channels (8).
Among the genes that can initiate tumorigenesis, many 
are closely linked to metabolic regulation. In this context, the 
biosynthetic processes required to divide and create daughter 
cells are equally important for tumor growth as is bioenergetics. 
Because of the preference for aerobic glycolysis in cancer cells, 
the glucose-derived metabolite feed into the tricarboxylic acid 
cycle is reduced. Thus, cancer cells typically have an increased 
reliance on alternative biomolecules to replenish Krebs cycle 
intermediates, and the amino acid glutamine is such a metabo-
lite (9). The anabolic prerequisites for these pathways are met if 
the glutamine metabolism generates NADPH, which restores 
oxaloacetate. Two necessary biosynthetic activities by prolifer-
ating tumor cells entail the production of ribose-5-phosphate 
for nucleotide biosynthesis and the production of fatty acids for 
lipid biosynthesis. The prevalent glutaminolysis in transformed 
cells enables the use of glucose carbon for lipid, protein, and 
nucleotide synthesis (10, 11). This model is supported by 
observations that several signaling pathways implicated in cell 
proliferation also regulate metabolic pathways that incorporate 
nutrients into biomass and that certain cancer-associated muta-
tions enable the cells to acquire and metabolize nutrients in a 
manner conducive to anabolism rather than to efficient ATP 
production (12).
The transcription factors YAP and TAZ, mediators of the 
Hippo pathway, promote organ growth, tumor cell prolifera-
tion, and cancer aggressiveness. When cells actively incorporate 
glucose and route it through glycolysis, YAP/TAZ transcription is 
fully active. When glucose metabolism is blocked or glycolysis is 
reduced, YAP/TAZ activity is decreased. Accordingly, glycolysis 
is required to sustain YAP/TAZ pro-tumorigenic functions, and 
YAP/TAZ is required for the full deployment of glucose growth-
promoting activity (13).
TRAveLeRS: THe MeTABOLiSM 
OF DeADHeReNT CeLLS
The dissemination of transformed cells is an integral character-
istic of cancers, but it is absent from benign growths. Metastases 
manifest clinically at advanced disease stages. While the major 
limiting factor in cancer spread is the death of the tumor cells 
before their implantation into target organs (14–16), a fraction 
of the released malignant cells can survive in the circulation for 
extended periods of time. The molecular programs of metastasis 
act to promote tumor progression, not growth or extension of 
life span (17, 18). Besides inducing directed migration and inva-
sion, they support adhesion-independent survival, which is more 
critical to the process of cancer metastasis than organ-specific 
homing (19). An excess of anchorage independence is pathogenic 
in cancer spread.
To accomplish survival after deadhesion, metastasis genes affect 
metabolic adjustments that are distinct from the Warburg effect. 
Untransformed non-hematopoietic cells (with the exception of 
tissue-resident stem cells) undergo anoikis consecutive to losing 
contact with their substratum. In these healthy cells, anchorage 
deprivation causes an impairment in glucose transport, a deficit 
in ATP (i.e., in chemical energy) and consecutive programed 
cell death (anoikis) (20). Cancer cells that have been released 
from a primary tumor need to overcome the energy shortfall to 
survive and form metastases. Consistent with these requirements, 
increased cancer invasiveness under anchorage-deprived condi-
tions is associated with higher mitochondrial activity, elevated 
ATP production, pyruvate uptake, and oxygen consumption (21).
In cancer cells that have been shed from the initiating neo-
plasm, the gene products of metastasis support enhanced energy 
generation, manifested in elevated ATP synthesis. Biochemical 
processes associated with the mitochondria may satisfy an 
increased energy requirement once these cells lose contact with 
the substratum. Variant forms of the cytokine osteopontin act 
as autocrine inducers. Osteopontin is a metastasis gene product 
that supports the progression of over 30 malignancies (22, 23). 
The protein exists in three splice variants, dubbed osteopontin-a, 
-b (lacking exon 5), and -c (lacking exon 4) (19). The variants 
osteopontin-b and -c have only been observed in transformed 
cells, and they are never expressed without the full-length gene 
product osteopontin-a. The distinct splice forms may synergize 
in support of anchorage-independent survival. Osteopontin-a 
increases the levels of glucose in deadherent cells. Signaling via 
osteopontin-c upregulates peroxides as well as intermediates of 
the hexose monophosphate shunt and glycolysis, which utilize 
the available glucose and can feed into the tricarboxylic acid 
cycle. Consecutively, the cellular ATP levels are elevated (24, 25). 
The role of the cancer-specific splice variants may account for 
the inability of non-transformed cells (which do not splice the 
osteopontin RNA) to overcome anoikis.
Elevated levels of hydrogen peroxide mediate metabolic 
changes that allow increased energy production, deadherent 
survival, and consecutive metastatic spread. Whereas research 
has widely focused on the potential pro-apoptotic functions of 
hydrogen peroxide (also note one of the teleological models for 
the Warburg effect), a growing literature that describes peroxide 
as essential for cancer metastasis (1) has received less attention. 
Anchorage-independent expansion is supported by peroxide 
signaling (26–28), which is tied to ATP generation, albeit through 
incompletely elucidated mechanisms. A hypothesis suggests 
that hydrogen peroxide inhibits anoikis through the suppres-
sion of caveolin-1 ubiquitination and degradation. Caveolae– 
mitochondria interaction regulates the adaptation to cellular 
stress by modulating the structure and function of the mito-
chondria. Through this mechanism, caveolin-1 is a key protein 
involved in tumor metastasis. An alternative hypothesis implies 
that ATP-sensitive potassium channels (KATP channels) can be 
activated by hydrogen peroxide in the mitochondrial membrane 
and exert anti-apoptotic effects, thus linking bioenergetics and 
survival. Either one of these interactions (potassium channels or 
caveolin) could account for the oxidative effects of osteopontin-c.
Anti-anoikis signals may be transduced via peroxides. The 
mitochondria generate reactive oxygen species, predominantly 
through their complex III. These are required for K-RAS-
mediated anchorage-independent growth, which is accomplished 
via regulation of the ERK/MAPK signaling pathway (29). Escape 
from anoikis through the production of reactive oxygen species 
FiGURe 1 | Glutamine in cancer cell metabolism. At various stages, glutamine plays critical roles in the metabolic skewing within cancer cells. The reason may 
be its central place in pathways associated with Warburg’s anabolism (via NADPH), energy generation during deadhesion, and hypoxic responses. Through its 
connection to NADPH production, glutamine also maintains the cellular redox balance via glutathione regeneration.
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can also be mediated by oxidation and activation of the tyrosine 
kinase SRC, which results in the transduction of a survival signal 
(30). While the upregulated oxidoreductases are confirmed 
important mediators of deadherent survival, the modalities by 
which the K-RAS and SRC pathways may affect metabolism in 
cancer cells are only now being elucidated. K-RAS may induce 
a non-canonical, but essential pathway of glutamine use in 
pancreatic cancers. Whereas most healthy cells use glutamate 
dehydrogenase to convert glutamine-derived glutamate into 
α-ketoglutarate in the mitochondria, pancreatic cancer cells 
transport glutamine-derived aspartate into the cytoplasm, where 
it is converted via oxaloacetate and malate, the further metabo-
lism of which ostensibly increases the NADPH/NADP+ ratio 
required to maintain the cellular redox state (31).
ATP ReGeNeRATiON: THe SeRiNe–
GLYCiNe–CReATiNe PATHwAY
Some of the metabolites that are upregulated by osteopontin-c, 
such as serine, glycine, and glycerol, are typically elevated in 
aggressive cancers. Glycine pathways may contribute to both, 
tumor growth and cancer dissemination. These molecules have 
emerged as potential targets for anticancer treatment strategies.
Adenosine triphosphate can be generated via the respira-
tory chain or via glycine and creatine in deadherent cells. The 
glycine pathway is frequently upregulated in cancer progression; 
in breast cancer, the splice variant osteopontin-c is the inducer 
(25). Osteopontin-c signaling increases the levels of glutamate 
and glycine as well as its metabolic product creatine, which may 
regenerate cellular ATP independently of the mitochondria. The 
elevated production of glycine and ensuing ATP regeneration via 
creatine supports anchorage-independent cell survival, in part 
through an increase in glutaminolysis (Figure 1). Furthermore, 
glycine may form sarcosine via N-methylation. Sarcosine is a 
metabolite that is highly elevated during prostate cancer progres-
sion to metastasis (32).
Glycine consumption and expression of the associated mito-
chondrial biosynthetic pathway are strongly correlated with the 
rates of proliferation in diverse cancer cells (33, 34). Even though 
glycine is a non-essential amino acid, which can be endogenously 
synthesized, the demand for it may exceed the endogenous syn-
thesis capacity in rapidly proliferating cancer cells. By contrast, 
in slowly proliferating cells, glycine synthesis may exceed the 
demand. The purpose for the amino acid is twofold. Glycine is 
utilized for de novo purine nucleotide biosynthesis in some rap-
idly proliferating cells. Utilization of one-carbon groups derived 
from glycine for cellular methylation reactions may be important 
in other cancer cell types.
GROUP DYNAMiC: MeTABOLiC CeLL–
CeLL iNTeRACTiONS
Stromal cells that surround a tumorous growth may enable the 
acquisition of a pro-invasive metabolic profile in the cancer 
cells. Despite aerobic conditions, glycolysis may be induced in 
mesenchymal stem cells that are in proximity to osteosarcoma 
cells. These untransformed cells then secrete lactate via the 
transporter MCT4. The tumor cells import this lactate because of 
their MCT1 expression, converting it to pyruvate and introducing 
it into the Krebs cycle. Thus, oxidative phosphorylation and ATP 
production are increased in osteosarcoma cells by surrounding 
mesenchymal stem cells via oxidative stress. This mechanism 
enhances their aggressive behavior (35).
The levels of P62 are reduced in the stroma of various tumors. 
This loss in the stromal fibroblasts results in increased tumori-
genesis of epithelial prostate cancer cells through the regulation 
of the cellular redox balance. Underlying is an mTORC1/c-Myc 
pathway of stromal glucose and amino acid metabolism, which 
causes increased stromal IL-6 production that is required for 
tumor promotion. Thus, P62 is an anti-inflammatory tumor sup-
pressor that acts through the modulation of metabolism in the 
tumor stroma (36).
FiGURe 2 | Publications on cancer metabolism. A search in PubMed 
with the keywords “cancer” and either “metabolism” or “glycolysis” or 
“Warburg” through 2015 indicates the recent surge in activity within the field. 
Note the logarithmic scale of the y-axis.
5
Weber Cell Metabolism during Cancer Progression
Frontiers in Oncology | www.frontiersin.org December 2016 | Volume 6 | Article 257
THe LATe STAGe
During early stages of transformation, tumor cells acquire gain-
of-function mutations in oncogenes or loss-of-function mutations 
in tumor suppressor genes that cause excessive proliferation and 
anti-apoptosis. As the transformed cells multiply, they outgrow 
the diffusion limits of oxygen, thus, becoming hypoxic. Because 
of increased glycolysis, more lactic acid is generated, which 
makes the lesions acidic. Even though new blood vessels are 
formed in cancer angiogenesis, they are disorganized and cannot 
effectively alleviate this state. One of the important pathophysi-
ological properties of advanced stage tumors is the prevalence of 
lactacidosis, hypoxia, and low glucose.
Human cells, non-transformed and transformed, are spe-
cifically equipped to sense the available oxygen in their micro-
environment and respond to changes. The hypoxia-inducible 
transcription factors HIF-1 and HIF-2 coordinate the adaptive 
cellular response to low-oxygen tension. Under normoxic condi-
tions, prolyl hydroxylases use oxygen as a substrate to hydroxylate 
key proline residues within the α subunits of HIF-1 and HIF-2. 
This mechanism allows the tumor suppressor VHL (an E3 ubiq-
uitin ligase) to target these α subunits for proteasomal degrada-
tion, thus preempting a low-oxygen response. Under hypoxic 
conditions, prolyl hydroxylase activity is suppressed, resulting 
in HIF-α stabilization and translocation to the nucleus. There, 
HIF-α subunits dimerize with aryl hydrocarbon receptor nuclear 
translocator, recruit transcriptional coactivators such as p300/
CBP, and bind to hypoxia-responsive elements in target genes to 
activate transcription. They induce gene expression programs, 
which regulate glucose uptake and metabolism to affect prolifera-
tion and survival.
Once a cancer mass has grown to a certain size, the genetic 
programs of transformation act in a non-conducive environment. 
The characteristic metabolic conditions of advanced tumors 
(lactacidosis, hypoxia, and low glucose) activate unique intra-
cellular signals (37). Because glycolysis constitutes a common 
metabolic pathway in cancer cells that leads to the generation and 
accumulation of high levels of lactic acid, their intracellular pH 
drops substantially. In this setting, the cancer cells maintain their 
homeostasis in part through the actions of carbonic anhydrases. 
These enzymes catalyze the reversible hydration of carbon dioxide 
and thus contribute to pH maintenance. Carbonic anhydrase IX 
(CAIX) is a membrane-bound enzyme that catalyzes the conver-
sion of water and carbon dioxide to bicarbonate ions and protons, 
extracellularly. These bicarbonate ions are then transported 
inside the cells, elevating the intracellular pH toward physiologic 
levels, so that cell survival is assured. Through the same process, 
CAIX leads to an accumulation of protons extracellularly, which 
makes the microenvironment more acidic. Acidification of the 
extracellular space could support cancer cell motility and increase 
invasion with resulting metastasis formation. CAIX may be over-
expressed in hypoxic cancer cells as a result of increased glycolysis 
and acidic pH. The enzyme is a downstream mediator of HIF-1α, 
which is activated by hypoxia.
HIF activity in hypoxic cells promotes the conversion of glucose 
to lactate, thus preventing its utilization in the Krebs cycle. A loss 
of HIF regulation by VHL, and resultant HIF hyper-activation, is 
sufficient to switch the input onto the Krebs cycle from mostly glu-
cose derived to glutamine derived. Intracellular citrate deficiency 
may promote this switch. Cancer cells in this state use glutamine 
to generate citrate and lipids through the reductive carboxylation 
of glutamine-derived α-ketoglutarate. Consistently, VHL defi-
ciency sensitizes cancer cells to the inhibition of glutaminase, the 
enzyme that catalyzes the first step of glutamine metabolism (9).
THe eYeS OF THe ReSeARCHeR
We have learnt that the intermediary pathways for energy gen-
eration are skewed in cancer cells, such that they favor aerobic 
glycolysis in primary tumors and stimulation of ATP generation 
in disseminating cancer cells. High-profile publications on glyco-
lysis versus oxidative respiration have attracted scientists in the 
field and have stimulated additional research into energy path-
ways. Because the stage was set, the same core pathways that had 
been pinpointed early on have been investigated over and over 
(Figure 2). The self-amplifying way, in which the research has been 
conducted, may have attributed disproportionate importance to 
glycolysis and its immediately connected metabolic processes. 
While more recent studies have ventured toward the analysis of 
branching pathways (such as the serine–glycine– creatine con-
nection), energy generation has been the broad area of interest. 
Newer theories have raised the possibility that anabolism may 
equally importantly be adjusted in cancer cells (11). It is conceiv-
able that pathophysiology—specifically in cancer—alters the 
metabolism more extensively than is thus far known. Research 
may need to expand its focus from glucose utilization and energy 
generation to the processing of other sugars and lipids, to the 
homeostasis of NADH and NADPH, and to the biosynthesis of 
nucleic acids, proteins, and other cellular components.
Besides the major energy source glucose, transformed cells 
can use alternative energy supplies. Non-glycolytic pathways are 
FiGURe 3 | PKB associated signal transduction pathways. PKB is an essential mediator of the lipid kinase signal transduction pathway. It exerts effects that 
lead to cell cycle progression, cell survival, and regulation of cell size. For each of these outcomes, multiple signaling intermediates synergize to induce the resultant 
biological effect. PI 3,4,5 P3, phosphatidylinositol 3,4,5-trisphosphate [adapted from Ref. (17)].
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operational in cancers even under hypoxic conditions. Among 
them, fatty acid oxidation may be a dominant bioenergetic 
pathway in prostate cancer cells (38). Fatty acid synthase, a key 
enzyme of the lipid metabolism, is upregulated in many cancers. 
Drug- and radiation-resistant tumor cells use fatty acid to sup-
port mitochondrial oxygen consumption when glucose becomes 
limited. Specific fatty acid synthase inhibitors may possess anti-
tumor activity.
Activated via receptors for PDGF, insulin, MET, and CSF-1, 
the proto-oncogene product phosphatidylinositol 3′-kinase (PI 
3-K) has important metabolic functions (Figure 3). It catalyzes 
the synthesis of phosphatidylinositol 3,4,5-trisphosphate or phos-
phatidylinositol 3,4-bisphosphate, which are ligands for Plekstrin 
homology domains in various proteins. It also associates with 
and activates the proto-oncogene product PKB. Ensuingly, PKB 
signaling plays key roles in cell cycle progression, cellular sur-
vival, and managing increased cell mass. The downstream target 
of this cascade, mammalian Target of Rapamycin (mTOR), is a 
serine/threonine kinase that oversees cell growth and metabolism 
in response to growth factors and nutrients. mTOR also senses 
oxygen and energy levels. It acts as a central regulator of cell size. 
mTOR controls biogenesis based on the availability of nutrients 
by activating RSK (P70 ribosomal S6 kinase), which enhances the 
translation of mRNAs that have 5′ poly-pyrimidine tracts. PI 3-K 
inhibits the tumor suppressing serine–threonine kinase LKB1, 
which is frequently lost in cancers, especially in lung cancers. 
LKB1 links cell metabolism to growth control and cell polarity. 
It phosphorylates and activates the central metabolic sensor 
AMP-activated protein kinase (AMPK). AMPK is a metabolic 
switch that governs glucose and lipid metabolism in response to 
alterations in nutrients and intracellular energy levels. The kinase 
controls anabolic pathways related to cell growth (39). The PI 3-K 
pathway has gained attention as a potential target for metabolic 
and anti-proliferative treatment in patients with cancer.
The mevalonate pathway may control YAP/TAZ transcrip-
tional activity via its rate-limiting enzyme, HMG-CoA reductase. 
The geranylgeranyl pyrophosphate produced by the mevalonate 
cascade is required for the activation of RHO GTPases that acti-
vate YAP/TAZ. In tumor cells, the oncogenic cofactor mutant P53 
induces SREBP transcriptional activity, which causes increased 
levels of mevalonate and consecutive activation of YAP/TAZ. 
The expression of receptor for hyaluronan-mediated motility 
(RHAMM) is regulated by the convergence of mevalonate and 
Hippo pathways onto YAP/TEAD, which controls RHAMM 
transcription and consequently supports breast cancer cell 
migration and invasion. Expression of the breast cancer sus-
ceptibility gene RHAMM is tightly controlled in healthy tissues 
but elevated in many tumors, contributing to tumorigenesis and 
metastases (40, 41).
iMPLiCATiONS FOR CANCeR THeRAPY
The characteristics of transformed cells have generated an oppor-
tunity to target their metabolism with drug treatment, a concept 
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referred to as metabolic intervention (42). Existing regimens have 
concentrated on the Warburg effect, hypoxia or the PI 3-K, and 
mevalonate pathways.
warburg effect
Because of metabolic and mitochondrial defects, tumor cells 
often preferentially use glycolysis to generate ATP, even in the 
presence of oxygen, the phenomenon known as the Warburg 
effect. Dichloroacetate (DCA, Ceresine) is an inhibitor of 
mitochondrial pyruvate dehydrogenase kinase, which inhibits 
pyruvate dehydrogenase, a gatekeeping enzyme for the entry of 
pyruvate into the tricarboxylic acid cycle. DCA treatment may 
reactivate mitochondrial respiration in tumor cells, induce their 
selective killing, and suppress cancer growth (8). The preferential 
targeting of cancer cells by this agent occurs through two mecha-
nisms. DCA shifts the metabolism toward aerobic respiration, 
such that depolarization of the mitochondrial membrane induces 
the release of pro-apoptotic factors. DCA promotes increased 
hydrogen peroxide generation, which activates potassium chan-
nels. Kv1.5 inhibits the calcium-dependent transcription factor 
NFAT, which impairs apoptosis. The activation of Kv1.5 may 
decrease cellular potassium, thus activating caspases and trigger-
ing apoptosis.
Dichloroacetate is used to treat hyperglycemia in diabetes 
mellitus, because it stimulates peripheral glucose utilization 
and inhibits gluconeogenesis through its effect on pathways of 
the intermediary metabolism. By decreasing circulating lipid 
and lipoprotein levels, it suppresses lipogenesis and cholesterol-
genesis in patients with acquired or hereditary disorders of the 
lipoprotein metabolism. By stimulating the activity of pyruvate 
dehydrogenase, DCA facilitates the oxidation of lactate and 
decreases morbidity in acquired and congenital forms of lactic 
acidosis. The drug is dehalogenated to monochloroacetate and 
glyoxylate, from which it can be further catabolized to glycolate, 
glycine, oxalate, and carbon dioxide. At sustained, higher doses, 
there is an increased risk of neurotoxicity and gait disturbance. 
DCA can cause a reversible peripheral neuropathy that may be 
related to thiamine deficiency and may be ameliorated or pre-
vented with thiamine supplementation. At high doses, the drug 
itself can be carcinogenic.
The indazole carboxylate lonamidamine suppresses aerobic 
glycolysis in cancer cells but enhances it in untransformed cells, 
likely through the inhibition of mitochondrial hexokinase. This 
causes a reduction in cellular ATP levels. The drug may also act 
as a putative ligand for adenine nucleotide translocator (exports 
ATP from the mitochondrial matrix and imports ADP into the 
matrix) that triggers apoptosis. Lonidamine is in clinical trials for 
the treatment of brain tumors.
Hypoxia
Distinct from the Warburg effect, late-stage tumors often incur 
hypoxia because they have outgrown their blood and oxygen 
supply. As a hypoxia-inducible transmembrane glycoprotein, 
CAIX catalyzes the rapid interconversion of carbon dioxide and 
water into carbonic acid, protons, and bicarbonate ions, help-
ing to maintain acidification of the tumor microenvironment 
and enhance resistance to cytotoxic therapy in some hypoxic 
tumors. Methazolamide (N-[5-(aminosulfonyl)-3-methyl-1,3,4-
thiadiazol-2(3H)-ylidene]-acetamide) is a sulfonamide derivate 
that inhibits tumor-associated CAIX (43). Thus, it may cause 
increased cell death in hypoxic tumors. Common adverse reac-
tions, occurring most often early in therapy, include paresthe-
sias, tinnitus, fatigue, malaise, loss of appetite, taste alteration, 
gastrointestinal disturbances (nausea, vomiting, and diarrhea), 
polyuria, and occasional instances of drowsiness and confusion. 
The drug can cause metabolic acidosis and electrolyte imbalance. 
Transient myopia subsides upon diminution or discontinuance 
of the medication. Rare but dangerous adverse reactions to sul-
fonamides include toxic epidermal necrolysis (Stevens–Johnson 
syndrome), fulminant hepatic necrosis, agranulocytosis, or 
aplastic anemia. Methazolamide should be used with caution in 
patients on steroid therapy because of the potential for develop-
ing hypokalemia. Under concomitant use of high dose aspirin, 
carbonic anhydrase inhibitors can lead to anorexia, tachypnea, 
lethargy, coma, or death.
Pi-3-Kinase Pathway
In many cancers, the phosphatidylinositol 3′-kinase pathway is 
upregulated, either by elevated levels of insulin or IGF or by loss-
of-function mutations of the tumor suppressor PTEN. Obesity 
and diabetes are accompanied by increased cancer risk, which 
may be due to high circulating levels of the growth factors insulin 
and IGF. Diabetics treated with metformin have 25–40% reduced 
incidence of cancer compared to those who receive insulin as 
therapy or take sulfonylurea drugs that increase insulin secre-
tion from the pancreas. Metformin activates the enzyme AMPK 
in the liver, which then reduces the synthesis and secretion of 
glucose, thereby lowering the blood glucose levels. The drug also 
downregulates the blood insulin and IGF levels. Furthermore, 
metformin stimulates the tumor suppressor gene LKB1. Due to 
these properties, metformin is under investigation for cancer 
treatment or prevention.
Mevalonate Pathway inhibitors
Statins are pharmacologic inhibitors of HMG-CoA reductase. 
They are used as lipid-lowering medications. Statins reduce car-
diovascular disease and mortality in high-risk patients. The class 
of drugs includes atorvastatin, fluvastatin, lovastatin, pitavastatin, 
pravastatin, rosuvastatin, and simvastatin. Adverse effects may 
comprise muscle pain, increased risk of diabetes mellitus, liver 
damage, and rare but severe muscle damage. As HMG-CoA 
reductase is the rate-limiting enzyme of the mevalonate pathway, 
statins have potential application in anticancer treatment to 
inhibit YAP/TAZ. While the literature is not conclusive on the 
subject, there are reports of reduced risk for certain cancers under 
statin therapy.
PROSPeCTS
The observation that cancer cells alter their metabolism compared 
to healthy cells has been firmly established. More recent research 
has dissected various phenotypic manifestations of the metabolic 
changes according to intrinsic, deadherent, stromal-induced, 
or late-stage conditions. Despite this progress, it is remarkable 
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how many gaps in knowledge still exist. The pathophysiologi-
cal purpose of the Warburg effect is incompletely understood. 
Hypotheses to explain the mechanism, through which peroxide 
signaling increases the cellular ATP levels after deadhesion, are 
yet untested. Pathways outside hexose monophosphate shunt, 
glycolysis, and tricarboxylic acid cycle have not been subjected to 
extensive research. While every new insight into cancer generates 
a desire to derive therapeutic applications, the limited under-
standing of the multiple molecular connections compromises the 
development of efficacious strategies.
Historically, the challenge for anticancer therapy has been 
the lack of qualitative differences between tumor cells and host 
cells. In infectious diseases, antibiotic therapy has been so suc-
cessful because it targets molecules of the pathogens that are 
highly distinct from humans, thus achieving very manageable 
adverse effects. As cancer cells are derived from self, this benefit 
was long not available to anticancer drug treatment. Therefore, 
conventional chemotherapy drugs, which rather non-specifically 
target cell division or DNA synthesis, have been fraught with 
high toxicity (predominantly to the rapidly proliferating cells in 
the immune system, the gastrointestinal tract, and the hair) and 
moderate efficacy due to inevitable dose limitations. One of the 
major accomplishments in translating molecular biology research 
into clinical applications has been the targeting of mutated mol-
ecules that are causative and specific for cancer cells, including 
BCR-ABL, mutated EGFR, and HER2. Similarly, anti-metastasis 
drugs neutralize molecules that are rarely expressed in the adult 
healthy organism, such as VEGF or integrin αVβ3. The targeting 
of altered metabolic pathways has its focus on quantitative, not 
qualitative, differences between tumor and host cells. While it is 
unlikely that such a modality could stand on its own, it is con-
ceivable that anti-metabolism treatments may be added to other 
cancer therapies and may synergize in combination regimens. 
It will be important to bear in mind the metabolic differences 
among primary tumors (Warburg effect), metastasizing cancer 
cells (peroxide-driven ATP production), tumor cells under 
stromal influence (lactate uptake, inflammation), and late-stage 
cancers (hypoxia) so as to direct anti-metabolism agents safely 
and efficaciously.
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